Innovation in Neurological Disorders & Healthspan.
Lateral Pharma is an Australian biotechnology company dedicated to developing first-in-class therapeutics that address some of the greatest challenges in modern medicine. Our focus is on creating novel drugs that harness the body’s natural protective pathways to treat neurological disorders, including neuropathic pain and chronic neurodegenerative diseases.
By targeting LanC-like (LanCL) proteins, our research platform offers a new way to protect cells from stress, inflammation, disease and damage, paving the way for breakthrough therapies with global impact.
Our Research Focus
These programs reflect our focus on areas of high unmet need,
where innovation has the power to improve outcomes on a global scale.
High level of competence
Our Vision for First-in-Class Therapeutics
David Kenley
CEO
Andy Gearing
Chief Scientific Officer
Stuart Mudge
Chief Operating Officer
David Williamson
CFO & Company Secretary
At Lateral Pharma, we are driven by the belief that medical innovation should improve the health of patients while creating value for partners and investors.
Our vision is to be a leader in biotech innovation, developing therapies that redefine standards of care across neurological disorders and Healthspan. By combining scientific expertise with strategic collaboration, we are building a robust platform designed for scalability, precision, and long-term success.
Partner with us
Science based Breakthrough Discovery
Lateral Pharma’s scientific breakthrough is the discovery of a novel protective mechanism mediated by LanCL proteins, which play a vital role in helping cells stay healthy under conditions of stress. Building on this discovery, we have developed a new class of Stressed Cell Protective (SCP) drugs derived from human proteins that activate these natural protective pathways.
Our SCP drugs have demonstrated safety and effectiveness across a range of preclinical models, including neuropathic pain, Alzheimer’s disease, and lung infections.
Lateral Pharma has successfully completed a clinical trial with LAT8881 in human sciatica, a condition categorised by neuropathic pain.
Our lead program, LAT9997*, an optimised form of LAT8881, is a subcutaneous injection being developed for the treatment of neuropathic pain and is preparing to enter clinical trials in the near future.
Follow-on programs are focused on identifying SCPs drugs suitable for oral administration for the treatment of neurological diseases, as well as expanding into new indications that support healthy ageing and Healthspan.
Partner with us
Building a Legacy in Drug Discovery and Clinical Progress
Founded in Melbourne, Australia, Lateral Pharma was established to translate scientific discoveries, with origins in the early work of Frank Ng from Monash University, into practical health solutions for patients who have limited treatment options. Our founder, David Kenley OAM, is driven by the desire to leave a legacy for future generations of medications with improved efficacy and safety.
Building on years of research and collaboration with world-class partners, we have advanced a unique pipeline of LanCL-targeting SCP drugs, including our lead candidate LAT9997. With clinical validation and a proven safety record, our compounds represent a promising future for diseases where traditional treatments fall short. From early-stage discovery through to clinical evaluation, our team has remained focused on delivering innovation that can transform lives.
Industry's leading experts
Investing in the Future of Biotech Innovation
We are positioned at the forefront of drug discovery with a pipeline that is both scientifically innovative and commercially attractive. Our research has already produced compelling clinical and preclinical results, supported by strong safety data and published findings. By focusing on areas of high unmet need, we aim to deliver first-in-class therapeutics that improve quality of life for patients worldwide. For investors and collaborators, Lateral Pharma represents a unique opportunity to engage with a company that combines clinical progress, biotech innovation, and scalable drug discovery.
We invite you to join us in shaping the future of medicine.
Through innovation, collaboration, and commitment, Lateral Pharma is shaping the future of medicine. We invite partners, investors, and researchers to join us in our mission to develop transformative therapies and change lives.